ANIP ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc (ANIP) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 86% planned / 14% discretionary
Largest single sale: $401.2K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| CAREY STEPHEN P. | SVP & CFO | Sell 10b5-1 | 2,850 | $72.80 | $207.5K | 171,843 −1.6% of holding | |
| Lalwani Nikhil | PRESIDENT & CEO | Sell 10b5-1 | 5,400 | $74.30 | $401.2K | 344,489 −1.5% of holding | |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell 10b5-1 | 500 | $75.48 | $37.7K | 74,424 −0.7% of holding | |
| Gutwerg Ori | SVP, GENERICS | Sell | 3,162 | $77.00 | $243.5K | 75,534 −4% of holding | |
| CAREY STEPHEN P. | SVP & CFO | Sell 10b5-1 | 2,850 | $81.36 | $231.9K | 174,693 −1.6% of holding | |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell 10b5-1 | 500 | $81.84 | $40.9K | 77,390 −0.6% of holding | |
| CAREY STEPHEN P. | SVP & CFO | Sell 10b5-1 | 3,313 | $86.00 | $284.9K | 177,543 −1.8% of holding | |
| CAREY STEPHEN P. | SVP & CFO | Sell 10b5-1 | 2,850 | $84.12 | $239.7K | 177,543 −1.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.